← Back to headlines
Aurinia Pharmaceuticals Eyes Growth Following LUPKYNIS Patent Settlement with Teva
Analysts evaluate whether Aurinia Pharmaceuticals' recent patent settlement for its kidney disease drug LUPKYNIS with Teva could drive significant stock gains for investors.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
